Matsuo K, Machida H, Matsuzaki S, et al. - To report the evolution of population-based statistics for rare epithelial ovarian cancers, researchers undertook this retrospective observational analysis assessing the Surveillance, Epidemiology, and End Results Program from 1988 to 2016. They fitted a propensity score matching to contrast overall survival of clear cell (OCCC), mucinous (MOC), and low-grade serous (LGSOC) ovarian cancers vs high-grade serous ovarian cancer (HGSOC). A diagnosis with stage I disease was more likely in OCCCs and MOCs vs HGSOC. Findings revealed 2–7% of ovarian malignancies were OCCC, MOC, and LGSOC, and these showed different features as well as survival compared with HGSOC. While a favorable to comparable prognosis was reported for these rare tumors in early-stage disease, disproportionally poor survival was observed in advanced-stage OCCC and MOC. This emphasizes the requirement for further investigation into new treatment strategies.